Risankizumab
Drug Name(s): Skyrizi
Class: Biologics
Type: IL-23
Used for the treatment of psoriatic arthritis (PsA).
Dosage
Form(s): prefilled syringe, auto-injector
150mg/mL injection every 12 weeks after two starter doses
Special Instructions
Remove drug from refrigerator and allow it to reach room temperature before injection. Do not inject into areas where the skin is tender, bruised, inflamed or affect by psoriasis.
Women of childbearing age should use effective contraception during treatment.
Potential Side Effects
Bruising, itching, pain, redness or swelling at the injection site; feeling tired, fungal skin infections, headache, upper respiratory infections
Be Aware
This and all biologics suppress the immune system and may increase your risk of infections. Tell your doctor if you have an active infection. Do not start treatment if you have a serious or recurrent infection (such as pneumonia). You should be tested for tuberculosis before starting this medication. Do not get a live vaccine when taking biologics.
